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Hyperoxia results in increased aerobic
metabolism following acute brain injury
Arnab Ghosh1,*, David Highton1,*, Christina Kolyva2,
Ilias Tachtsidis2, Clare E Elwell2 and Martin Smith1,2,3
Abstract
Acute brain injury is associated with depressed aerobic metabolism. Below a critical mitochondrial pO2 cytochrome c
oxidase, the terminal electron acceptor in the mitochondrial respiratory chain, fails to sustain oxidative phosphorylation.
After acute brain injury, this ischaemic threshold might be shifted into apparently normal levels of tissue oxygenation.
We investigated the oxygen dependency of aerobic metabolism in 16 acutely brain-injured patients using a 120-min
normobaric hyperoxia challenge in the acute phase (24–72 h) post-injury and multimodal neuromonitoring, including
transcranial Doppler ultrasound-measured cerebral blood flow velocity, cerebral microdialysis-derived lactate-pyruvate
ratio (LPR), brain tissue pO2 (pbrO2), and tissue oxygenation index and cytochrome c oxidase oxidation state (oxCCO)
measured using broadband spectroscopy. Increased inspired oxygen resulted in increased pbrO2 [pbrO2 30.9 mmHg
p< 0.001], reduced LPR [LPR 3.07 p¼ 0.015], and increased cytochrome c oxidase (CCO) oxidation
([oxCCO]þ 0.32 mM p< 0.001) which persisted on return-to-baseline ([oxCCO]þ 0.22 mM, p< 0.01), accompa-
nied by a 7.5% increase in estimated cerebral metabolic rate for oxygen (p¼ 0.038). Our results are consistent with an
improvement in cellular redox state, suggesting oxygen-limited metabolism above recognised ischaemic pbrO2 thresh-
olds. Diffusion limitation or mitochondrial inhibition might explain these findings. Further investigation is warranted to
establish optimal oxygenation to sustain aerobic metabolism after acute brain injury.
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Introduction
The brain relies on aerobic metabolism to meet its sub-
stantial energy needs and, in health, various mechan-
isms ensure that oxygen (and metabolic substrate)
supply is balanced to meet metabolic demand. This bal-
ance is often disturbed after acute brain injury in which
cerebral hypoxia–ischaemia is a key injury mechanism
associated with poor outcome, irrespective of brain
injury type.1–3 Speciﬁc neuroprotective therapies have
failed to translate into clinical beneﬁt4,5 and treatment
of severe acute brain injury therefore focuses on
avoiding or minimising secondary cerebral hypoxia–
ischaemia and consequent mitochondrial energy failure
by maintaining cerebral oxygen delivery at a level that
is suﬃcient to meet metabolic demand.6,7 Debate con-
tinues whether depressed aerobic metabolism, which is
common following acute brain injury, predominantly
reﬂects oxygen deprivation or a non-ischaemic meta-
bolic crisis.8,9
Mitochondria exist and function normally in a near
anoxic environment, facilitating a diﬀusion gradient for
oxygen transport from the microvasculature, and
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oﬀering protection from oxidant damage. Cytochrome
c oxidase (CCO), the terminal electron acceptor in the
mitochondrial respiratory chain, is responsible for
reducing oxygen to water. Its low Michaelis–Menton
constant (Km) for oxygen means that oxidative phos-
phorylation may continue unimpeded in isolated mito-
chondria with a pO2 less than 1 mmHg.
10 Below a
critical ischaemic threshold, CCO is reduced and,
importantly, oxygen then becomes a rate limiting sub-
strate decreasing oxidative phosphorylation.11,12
In health, changes of brain tissue pO2 within the
physiological range are not believed to inﬂuence cere-
bral oxygen consumption13 but, following acute brain
injury, a range of disturbances to oxygen transport and
its utilisation may complicate the relationship between
pO2 and metabolism. Classical ischaemia describes a
situation of insuﬃcient oxygen delivery, and therefore
of maximal extraction of oxygen from haemoglobin,
and is characterized by a combination of large oxygen
extraction fraction (OEF) measured by positron emis-
sion tomography (PET), cerebral oligaemia, and falling
cerebral metabolic rate for oxygen (CMRO2).
14
While prevalent early after acute brain injury, this pic-
ture is less common beyond the immediate period of
injury after stroke and traumatic brain injury (TBI).15
Metabolic dysfunction has been identiﬁed in the pres-
ence of apparently acceptable tissue oxygenation, where
both diﬀusion limited oxygen transport and mitochon-
drial dysfunction have been implicated as alternative
forms of restriction to oxidative metabolism in the pres-
ence of a normal interstitial tissue pO2 or OEF.
16
Multimodal neuromonitoring with brain tissue pO2
(pbrO2) and cerebral microdialysis-derived lactate:pyru-
vate ratio (LPR) have enabled investigation of the
relationship between oxygen delivery, cerebral tis-
sue oxygenation, and cellular redox status in vivo fol-
lowing TBI,16 aneurysmal subarachnoid haemorrhage
(SAH),17 and intracerebral haemorrhage (ICH).18,19
Clinical therapy protocols guided by changes in pbrO2
seek to maintain oxygen delivery and availability above
a ‘critical’ pO2 threshold for anaerobic metabolism.
20
Although overt ischaemia and anaerobic metabolism
has typically been described when pbrO2 falls below
10 mmHg, normobaric hyperoxia and hyperbaric
hyperoxia may improve LPR and CMRO2 after TBI
in the presence of pbrO2 values that are within or
above the normal physiological range.21–23 Vespa
et al.16 demonstrated metabolic dysfunction without
classical ischaemia after TBI based on observation of
elevated LPR and PET-derived OEF> 0.75. Others
have described a similar picture of metabolic dysfunc-
tion ‘without hypoxia’ in SAH and ICH.17 However, it
is diﬃcult to entirely rule out hypoxia as a cause of such
observations because of the absence of a subcellular
marker of oxygenation in these studies. Diﬀusion
limitation or an altered mitochondrial ischaemic
threshold could equally explain these ﬁndings. While
CCO oxidation status reﬂects the activity of the respira-
tory chain, it is also dependent on metabolic substrate
supply, ATP, oxygen, and mediators which modify the
Km for oxygen such as nitric oxide.
24 Understanding
the changes in CCO oxidation status may therefore
be a useful adjunct for the in-vivo investigation of dif-
fusion limitation and mitochondrial dysfunction after
acute brain injury.
We have developed an in-house optical technique,
incorporating hybrid spatially resolved broadband
and frequency domain near infrared spectroscopy
(NIRS), optimised for the measurement of the oxida-
tion state of CCO [oxCCO] in adult brain-injured
patients.25 Spatially resolved cerebral tissue oxygen sat-
uration, also called the tissue oxygenation index (TOI),
in association with concentrations of oxyhaemoglobin
([HbO2]), deoxyhaemoglobin ([HHb]) and [oxCCO]
may be used to investigate oxygenation of both the
microvasculature and mitochondria.12 A comprehen-
sive multimodal neuromonitoring array, including
pbrO2, microdialysis, transcranial Doppler-measured
cerebral blood ﬂow velocity and NIRS therefore
covers the entire oxygen cascade from the microvascu-
lature (TOI, HbO2, HHb) through the tissue intersti-
tium (pbrO2) to the mitochrondria ([oxCCO]), and has
potential to predict cellular redox status (microdialysis
LPR, [oxCCO]) and CMRO2 changes estimated using
NIRS and transcranial Doppler,26 and might therefore
diﬀerentiate between diﬀusion limited oxygen transport
and mitochondrial dysfunction.
The aim of this study was to investigate the oxygen
dependence of mitochondrial metabolism in vivo
following acute brain injury. We hypothesised that nor-
mobaric hyperoxia-induced increases in cerebral
oxygen availability would lead to an increase in CCO
oxidation and reduction in microdialysate LPR, sug-
gesting oxygen-limited mitochondrial oxidative metab-
olism at baseline.
Materials and methods
Study participants and protocol
After approval by the Research Ethics Committee of
the National Hospital for Neurology and Neurosurgery
and Institute of Neurology (04/Q0512/67) and repre-
sentative consent, recordings were carried out in
16 sedated, mechanically ventilated acute brain injury
patients requiring invasive neuromonitoring to guide
clinical management on the neurocritical care unit.
This was performed in accordance with the
Declaration of Helsinki. Inclusion criteria also included
baseline inspired fraction of oxygen (FiO2)
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less than 0.5. The patients were subject to a normobaric
hyperoxia protocol which consisted of a 60-min epoch
of baseline recording followed by two 60-min epochs in
which FiO2 was increased ﬁrst to 0.6 and then to 1.0,
and a ﬁnal 30-min epoch during which FiO2 was
returned to baseline values (Figure 1).
Monitored parameters
Systemic physiological monitoring included invasive
arterial blood pressure (ABP) and pulse oximetry
(SpO2) measured continuously, and measurement of
arterial blood gases (ABGs), including carbon dioxide
and oxygen partial pressures (paCO2 and paO2,
respectively). Middle cerebral artery blood ﬂow velocity
(Vmca) was measured using transcranial Doppler ultra-
sonography (DWL Doppler Box, Compumedics,
Singen, Germany). Invasive cerebral monitoring com-
prised pbrO2 (Licox, Integra Neurosciences, Plainsboro,
USA) and measurement of LPR by cerebral microdia-
lysis (M Dialysis AB, Stockholm, Sweden), with cath-
eters implanted via a cranial access device (Technicam,
Newton Abbot UK or Licox IP2, Integra
Neurosciences) or surgically at time of craniotomy. In
accordance with consensus guidelines, catheters were
placed in peri-lesional tissue in patients with focal
TBI or ICH, in the right frontal lobe in patients with
diﬀuse TBI, or tissue thought to be at risk of ischaemia
from vasospasm in patients with aneurysmal SAH.27
All non-invasive cerebral monitoring was conducted
ipsilateral to the invasive monitoring.
NIRS instrumentation and processing
The NIRS apparatus used in this study has been
described in detail elsewhere.28 In brief it comprises
two components – a multidistance broadband spectrom-
eter and a multidistance frequency domain spectrometer.
Chromophore concentration was derived from the
broadband spectroscopy component that incorporates
a 50 W halogen light source and lens-based spectrograph
based on a charge-coupled device camera (PIXIS
512f, Princeton instruments) using the UCLn algo-
rithm.29 Measurements were made simultaneously at
four source-detector separations (20/25/30/35mm). The
broadband spectrometer-derived concentrations of
HbO2, HHb and oxCCO from the 35mm separation
are reported here as we have previously shown that
this source-detector separation has the highest brain-
speciﬁcity, particularly for the measurement of oxCCO.25
The frequency domain component of the system utilises an
OxyPlexTS device (ISS Inc., Champaign, IL, USA) mod-
iﬁed with diodes emitting light at four wavelengths (690,
750, 790 and 850nm), and was used to derive the absolute
optical absorption and reduced scattering coeﬃcients
(ma and ms, respectively) as previously described,28 and
derivation of the diﬀerential pathlength factor using the
diﬀusion approximation.30 In this study, we report ms rec-
orded at 790nm. An individual diﬀerential pathlength
factor was calculated for each patient, based on the ma
and ms measured by the frequency domain spectrometer
during the initial minute of recording of the baseline
epoch. The TOI – deﬁned as [HbO2]/([HbO2]þ[HHb]) –
was calculated using spatially resolved spectroscopy.31 The
740nm–900nm wavelength range was used to resolve for
HbO2, HHb, and water, and TOI calculated using indi-
vidual scattering values measured with the frequency
domain system.25
NIRS data analysis was performed in Matlab 2010b
(Mathworks, Natick, MA). Diﬀerential concentrations
of HbO2, HHb and oxCCO ([HbO2], [HHb] and
[oxCCO], respectively) were calculated using the
UCLn algorithm.28–30 Changes in total haemoglobin
concentration ([HbT]) were calculated as
[HbO2]þ[HHb] and in haemoglobin diﬀerence
concentration ([HbDiﬀ]) as [HbO2] – [HHb].
Time (minutes)
0 60 210120 180
Baseline inspired oxygen
fraction (typically 30%)
Inspired oxygen fraction
 60%
Inspired oxygen fraction
 100%
Baseline
2
 Continuous NIRS monitoring: broadband and frequency-domain spectrometers
Microdialysis lactate-pyruvate ratio measured
Arterial blood gases measured
Figure 1. Normobaric hyperoxia protocol and measured variables.
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Data processing
After manual identiﬁcation and linear interpolation to
remove NIRS signal artefacts, mean values for each
monitored variable were calculated for individual
epochs for each patient. The continuously monitored
systemic and cerebral variables (including NIRS) were
synchronized, and a mean value from a period
comprising 50% of the epoch which was free from
noise was used for analysis. For intermittently sampled
variables (i.e. ABGs and microdialysate LPR), the mean
of all readings per epoch (minimum two per epoch) was
used as the summary variable for that epoch.
Relative estimated changes in CMRO2 (rCMRO2)
were estimated for the return-to-baseline epoch com-
pared to the baseline epoch using the NIRS Fick equa-
tion (equation (1)) described by Roche-Labarbe et al.32
rCMRo2¼ Vmca
Vmca0
:
SpO2TOI
SpO20TOI0
 
ð1Þ
Statistical analysis
We used GLIMMPSE, a validated model for power
calculation in linear mixed models,33 to conduct a
sample size calculation. Assuming an [oxCCO] stand-
ard deviation of 0.2mM in each epoch, a total of 16
patients are required to provide a power of 90% in
detecting [oxCCO] changes ofþ 0.1,þ 0.2 and
þ0.05mM during the FiO2¼0.6, FiO2¼1.0 and return-
to-baseline epochs.
Statistical analyses were carried out in R.34
Parameters of interest were analysed using a mixed
eﬀects model,35 modelling individual subjects as
random and epochs as ﬁxed eﬀects. The signiﬁcance
of the ﬁxed epoch eﬀect for each variable (i.e. the prob-
ability that the variable was the same across all four
epochs) was then estimated using the Likelihood Ratio
Test, comparing the mixed eﬀects model to a null model
comprising only random eﬀects. In variables with an
epoch eﬀect probability of <0.05, subsequent pairwise
comparison between baseline and subsequent FiO2
epochs (0.6 and 1.0 and return-to-baseline), was per-
formed using Bonferroni-corrected Wilcoxon signed-
rank tests. The Hodges–Lehman estimate was used to
calculate the (pseudo)median and per-epoch 95% con-
ﬁdence intervals. Relative changes in CMRO2 were
similarly treated, but no Bonferonni correction was
applied since only the baseline and return-to-baseline
epochs were compared. All data are expressed as (pseu-
do)median (95% conﬁdence interval) unless otherwise
stated. A Spearman correlation was used to assess the
relationship between baseline pbrO2 and LPR and the
LPR response to normobaric hyperoxia. Statistical
signiﬁcance was inferred at p< 0.05.
Results
The full study protocol was completed in all 16
patients. Patient characteristics are shown in Table 1.
Technical failure resulted in the loss of ABP and pbrO2
recordings for one patient but this patient was included
in all analyses, excluding these parameters. Baseline
levels for the physiological variables are shown in
Table 2, the epoch eﬀect for each variable in Table 3,
and changes in measured variables in Table 4 and
Figure 2.
Normobaric hyperoxia was associated with statistic-
ally signiﬁcant increases in paO2, SpO2 and pbrO2,
but there was no change in paCO2 during the study.
While a signiﬁcant overall epoch eﬀect for Vmca
Table 2. Physiological & optical variables at
baseline.
Variable Baseline value (IQR)
FiO2 0.325 (0.28–0.35)
paO2 (kPa) 15.7 (12.5–18.0)
paCO2 (kPa) 4.85 (4.65–4.97)
SpO2 (%) 99 (98–99)
MAP (mmHg) 91.5 (83.2–96.8)
Vmca (cm.s1) 52.1 (48.7–71.8)
pbrO2 (mmHg) 17.5 (12.0–24.4)
Microdialysate LPR 25.3 (23.5–33.5)
TOI (%) 72.8 (65.5–77.0)
DPF 9.33 (6.75–10.8)
ms (cm1) 11.1 (6.76–12.4)
DPF: differential pathlength factor; FiO2: inspired oxygen
fraction; IQR: inter-quartile range; MAP: mean arterial
blood pressure; LPR: lactate:pyruvate ratio; paO2: arterial
pO2; paCO2: arterial pCO2; pbrO2, brain tissue pO2; TOI:
tissue oxygenation index; SpO2: arterial oxygen saturation;
ms: optical reduced scattering coefficient; Vmca: middle
cerebral artery blood flow velocity.
Table 1. Demographic data.
Age (years) 46.5 (39.3–51.5)
Sex 6 male, 10 female
Primary diagnosis TBI 7
SAH 8
ICH 1
Time to study
(hours post injury)
36 (25.5–45)
Admission GCS 7 (4–9)
Note: Data expressed as median with IQR.
GCS: Glasgow coma score; ICH: intracerebral haemor-
rhage; SAH: subarachnoid haemorrhage; TBI: traumatic
brain injury.
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was observed, post hoc testing identiﬁed no single
epoch diﬀerence from baseline. Normobaric hyperoxia
was also associated with statistically signiﬁcant
increases in [oxCCO] and reductions in microdialy-
sate LPR during the 0.6 FiO2 ([oxCCO]þ 0.18,
p< 0.01; LPR 1.16, p< 0.01) and 1.0 FiO2
([oxCCO]þ 0.32, p< 0.001; LPR 3.07, p< 0.01)
epochs. These changes persisted in to the return-to-
baseline epoch ([oxCCO]þ 0.22 [p< 0.01] and
LPR 0.254 [p< 0.01]). Estimated CMRO2 was
higher in the return-to-baseline epoch compared to
the baseline epoch [CMRO2 107.5% of baseline
(95% CI 100.3% – 119.0%, p¼ 0.039)].
There were no changes in [HbT] during the study.
[HbDiﬀ] increased during the 0.6 and 1.0 FiO2 epochs
([HbDiﬀ]þ 1.18mM and þ2.17, respectively, both
p< 0.001), but there was no signiﬁcant change during
the return-to-baseline epoch compared to baseline.
There was a signiﬁcant increase in TOI during the 0.6
and 1.0 FiO2 epochs (TOI 2.8% and 6.0% respect-
ively, both p< 0.001), with no signiﬁcant change during
the return-to-baseline epoch. There were no signiﬁcant
changes in optical scattering measured at 790 nm
(epoch eﬀect p¼ 0.786). There was no correlation
between baseline pbrO2 or LPR and theLPR response
to normobaric hyperoxia (r¼0.04, p¼ 0.89; r¼ 0.01
p¼ 0.98, respectively).
Discussion
We have demonstrated that normobaric hyperoxia-
induced increase in pbrO2 is associated with increased
[oxCCO] and reduced LPR, suggesting a change in
mitochondrial redox status and the presence of
oxygen dependent metabolism above traditionally
described ischaemic thresholds. Our ﬁndings are con-
sistent with oxygen-limited metabolism in this cohort of
patients with acute brain injury, and suggest the pres-
ence of either oxygen diﬀusion limitation or mitochon-
drial dysfunction and hypoxia–ischaemia despite
‘normal’ values for pbrO2. Importantly, the [oxCCO]
and LPR changes are sustained when FiO2 is returned
to baseline after the period of hyperoxia, while the
markers of microvascular and brain tissue oxygenation
(TOI, [HbO2], [HHb], pbrO2) return to their pre-
hyperoxia values. This suggests that improvement in
cellular metabolism persists beyond the immediate
period of normobaric hyperoxia, a supposition sup-
ported by the elevation in estimated CMRO2 during
the return-to-baseline FiO2 epoch.
Although the mean baseline pbrO2 of 17.5 mmHg
in our study lies within some deﬁnitions of hypoxia–
ischaemia (<20 mmHg),36 the majority of previous
studies highlight <10 mmHg as a particular risk for
elevated LPR and PET markers of ischaemia.37,38 In
our study, both epochs of the hyperoxia protocol
resulted in elevation of pbrO2 well into its ‘normal’
physiological range, and there was a stepwise increase
in [oxCCO] and reduction in LPR as FiO2 was
increased from 0.6 to 1.0. These ﬁndings are not con-
sistent with classical hypoxia–ischaemia. There was also
no correlation between baseline pbrO2 or LPR and the
change in LPR, suggesting that hypoxia/ischaemia,
deﬁned by pbrO2 or LPR, does not aﬀect the brain’s
response to normobaric hyperoxia in this patient
group. This ﬁnding is unsurprising since the LPR was
consistently reduced (3.07 95% CI 4.38–1.61)
during normobaric hyperoxia despite diﬀerent baseline
values for pbrO2 and LPR.
Both oxygen diﬀusion abnormalities and mitochon-
drial dysfunction have been proposed as mechanisms
for oxygen becoming a rate limiting substrate for
metabolism.15,16,21 Delivery of oxygen to the mitochon-
dria is dependent on the gradient of oxygen tension as
well as the conductance of the tissues. During the study
period (24–72 h after ictus), cerebral oedema and hence
perivascular/cellular swelling and microvascular col-
lapse are important factors which increase the diﬀusion
distance from the microvasculature to mitochondria
and might necessitate increased oxygen tension to sus-
tain the rate of mitochondrial oxygen delivery.
However, our ﬁndings of sustained metabolic improve-
ment ([oxCCO], LPR, CMRO2) on return-to-baseline
FiO2 and therefore baseline paO2, and predicted
oxygenation gradients (see below), are not entirely con-
sistent with diﬀusion limitation as the only patho-
physiological process. They may also indicate reversal
Table 3. Epoch effects from likelihood ratio test.
Variable Chi-squared p
paO2 171 <0.001
pCO2 5.63 0.131
SpO2 64.8 <0.001
LPR 9.28 0.026
pbrO2 44.6 <0.001
Vmca 8.31 0.04
HbDiff 27.0 <0.001
HbT 4.5 0.21
oxCCO 15.1 0.002
TOI 22.3 <0.001
ms 1.06 0.787
HbDiff: haemoglobin concentration difference; HbT: total
haemoglobin concentration; LPR: lactate:pyruvate ratio;
oxCCO: cytochrome c oxidation state; paO2: arterial
pO2; paCO2: arterial pCO2; pbrO2: brain tissue pO2;
TOI: tissue oxygenation index; SpO2: arterial oxygen sat-
uration; ms: optical reduced scattering coefficient; Vmca:
middle cerebral artery blood flow velocity.
2914 Journal of Cerebral Blood Flow & Metabolism 37(8)
of mitochondrial dysfunction by normobaric hyper-
oxia. Baseline TOI was 73% in our study and this lies
within a physiologically ‘normal’ range for NIRS-
derived regional cerebral saturation.39 Assuming one-
quarter of blood volume is saturated arterial blood, this
predicts a venous saturation of 64% and approximate
venous pO2 of 33 mmHg (using the calculation from
Menon et al.15), and thus an average diﬀerence of 15.5
mmHg between venous blood (33 mmHg) and pbrO2
(17.5 mmHg). Similar comparisons using PET and
pbrO2 have described gradients of 10 mmHg and
27 mmHg in normal and impaired brain regions,15 so
our observations are consistent with only a moderate
diﬀusion distance between the microvasculature and
tissue interstitium. This further supports the notion
that isolated diﬀusion limitation is not the sole mech-
anism implicated in oxygen becoming a rate limiting
substrate for metabolism after acute brain injury.
CCO oxidation increased by 0.32mM during a mean
pbrO2 change of 30.9 mmHg in the 1.0 FiO2 epoch, and
returned to 0.22 mM during return-to-baseline FiO2.
Although the total concentration of CCO in the adult
human brain is unknown, it is approximately 5 mM in
rats.40 The CCO changes that we observed are therefore
likely to reﬂect an approximate 6% change in its oxi-
dation, which is higher than that observed in healthy
volunteers during increases in cerebral oxygen delivery
or during functional activation,25,28,41,42 but equivalent
to those described previously in TBI.22 The oxidation
status of CCO is modiﬁed by both mitochondrial
pO2 and metabolic factors (ADP, NAD:NADH), and
our ﬁndings are consistent with both an increase in aer-
obic metabolism and/or increased mitochondrial pO2.
Earlier studies have shown an association between cere-
bral oxygen delivery and CCO oxidation in healthy vol-
unteers25,43 and, in animal models, with brain ATP40
Table 4. Changes from baseline for measured variables data presented as (pseudo)median (95%
confidence interval.
Epoch
FiO2 0.6 FiO2 1.0 Return-to-baseline
[HbDiff] (mM) 1.18
(0.59–2.12)
2.17
(1.17–4.13)
0.30
(0.22–1.28)
[HbT] (mM) 0.13
(0.52–0.22)
0.46
(1.16–0.13)
0.44
(0.01–0.90)
[oxCCO] (mM) 0.18
(0.08–0.47)
0.32
(0.11–0.76)
0.22
(0.06–0.62)
TOI (%) 2.8
(1.8–5.6)
6.0
(3.4–10.9)
0.31
(2.6–2.8)
Relative CMRO2 (%) – – 107.5
(100.3–119.0)
 LPR 1.16
(1.93–0.455)
3.07
(4.38–1.61)
2.54
(4.38–0.475)
 pbrO2 (mmHg) 8.44
(5.19–12.2)
30.9
(21.6–43.4)
2.72
(1.76–9.46)
 MAP (mmHg) 1.19
(2.32–4.92)
1.48
(3.73–8.8)
0.56
(7.83–7.38)
 pCO2 (kPa) 0.15
(0.0333–0.258)
0.114
(-0.05–0.258)
0.203
(0.1–0.425)
 paO2 (kPa) 14.1
(11.3–17)
38.7
(35–42.3)
1.21
(1.99–0.1)
 SpO2 (%) 1.5
(1.00–2.00)
1.5
(1.01–2.00)
0.831
(1.16–0.778)
Vmca (cm.s1) 2.19
(1.23–5.62)
2.64
(2.09–7.47)
5.19
(0.45–11)
ms (cm1) 0.0168
(0.201–0.173)
0.0201
(0.394–0.297)
0.0785
(0.423–0.354)
FiO2: inspired oxygen fraction; CMRO2: cerebral metabolic rate for oxygen; HbDiff: haemoglobin concentration
difference; HbT: total haemoglobin concentration; LPR: lactate:pyruvate ratio; MAP: mean arterial blood pressure;
oxCCO: cytochrome c oxidation state; paO2: arterial pO2; paCO2: arterial pCO2; pbrO2: brain tissue pO2;
TOI: tissue oxygenation index; SpO2: arterial oxygen saturation; ms: optical reduced scattering coefficient;
Vmca: middle cerebral artery blood flow velocity
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Figure 2. Changes in markers of cerebral oxygen delivery and aerobic metabolism during normobaric hyperoxia showing (pseu-
do)median changes and 95% confidence interval error bars.
*p< 0.05; **p< 0.01; ***p< 0.001.
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and lactate44 concentrations. Likewise, the persistent
CCO oxidation in the return-to-baseline epoch in our
study suggests either increased aerobic metabolism
(consistent with the measured LPR and estimated
CMRO2) and/or an altered Km for O2. It is interesting
to note that nitric oxide is known to increase the Km of
CCO, and the proposed mechanism of action for nor-
mobaric and hyperbaric hyperoxia is the reversal of this
nitric oxide eﬀect thereby reducing the threshold at
which oxygen becomes a rate limiting step in oxidative
metabolism.24 Thus, our results could theoretically rep-
resent the breakdown of NO rather than a direct eﬀect
of elevated mitochondrial pO2. Hypoxia-inducible
factor 1a (HIF-1a) is another major hypoxia signalling
pathway which inhibits pyruvate dehydrogenase activ-
ity, a branch point controlling oxidative/anaerobic
metabolism, as well as a range of glycolytic enzymes.45
Although these eﬀects may also be modiﬁed by hyper-
oxia, it has also been suggested that a reduction in LPR
(as seen in our study) is more consistent with an
increase in oxidative metabolism since HIF-1a should
reduce lactate while maintaining LPR.21 While the
median reduction in LPR (3.07) during normobaric
hyperoxia in our study is not large, and of unlikely
clinical signiﬁcance in itself, it might reﬂect a small
volume of ischaemic tissue within the larger tissue
volume monitored by the microdialysis catheter.
Furthermore, when considered within the context of
the increases in aerobic metabolism shown by the
other monitoring modalities during normobaric hyper-
oxia, it is possible that this small improvement in LPR
might indicate patients with an oxygen-dependent def-
icit in aerobic metabolism that is amenable to treat-
ment. Further clinical studies are required to assess
the clinical relevance of such changes in LPR when
interpreted in association with other monitored vari-
ables of aerobic metabolism.
Our ﬁndings are consistent with those of several pre-
vious studies. Diringer et al. found no signiﬁcant
change in CMRO2 in a PET study of normobaric
hyperoxia in ﬁve TBI patients, but the small sample
size precludes deﬁnitive conclusions. A pilot study by
our group of eight patients with TBI found similar
changes in LPR (1.6) and [oxCCO] (þ0.21 mM)
during normobaric hyperoxia to those we report
here.22 Our current study builds on that pilot in three
important aspects – by including a larger number of
patients, using an improved NIRS apparatus with
patient-speciﬁc measures of diﬀerential pathlength
factor, and incorporating an estimate of CMRO2.
Nortje et al.21 also demonstrated that normobaric
hyperoxia in patients with TBI was associated with a
similar reduction in LPR (mean LPR reduced from 34.1
to 32.5) to our current study, but PET-measured
CMRO2 increased only in regions of interest with a
reduced CMRO2 at baseline. However, a smaller
study of eight patients with TBI, showed no improve-
ment in LPR during 3 h of normobaric hyperoxia.46
Our study demonstrated an improvement in markers
of aerobic metabolism during a short (120min) graded
hyperoxia challenge. Although [oxCCO], LPR and
CMRO2 remained partially elevated following return-
to-baseline FiO2, further assessments were not made
beyond this period so the longevity of the potential
metabolic beneﬁt of hyperoxia is uncertain. It must be
noted that hyperoxia has a variety of deleterious eﬀects
through generation of reactive oxygen species, induc-
tion of cytotoxic cytokines and immunosuppression,
and concerns exist regarding its prolonged use.
Kilgannon et al.47 identiﬁed an association between
supranormal paO2 and worsened outcome following
cardiac arrest, while Quintard et al.48 demonstrated
an association between normobaric hyperoxia and
increased microdialysate glutamate, a key mediator of
cerebral excitotoxicity, following TBI. While reactive
oxygen species are a major injury mechanism impli-
cated following cerebral ischaemia, they may be gener-
ated both by hypoxia (excess of reductive substrate) as
well as by the delivery of excessive oxygen.49,50 Thus,
oxygen therapy must be carefully controlled after acute
brain injury. Time-limited application of hyperoxia or
the use of pbrO2 to guide oxygen administration may
limit the potential deleterious eﬀects of unrestrained
oxygen use while minimising the risk of cerebral hyp-
oxia/ischaemia. A higher pbrO2 might be warranted
given the concerns with oxygen diﬀusion and mito-
chondrial inhibition 24–72 h post injury. Normobaric
hyperoxia frequently results in restoration of pbrO2
into what is usually considered to be a ‘normoxic’
range, and the consistent increases observed in markers
of aerobic metabolism even when pbrO2 is greater than
the physiological range21–23 might suggest the need for
a higher target. Future research should focus on the
relevance of higher pbrO2 targets and additional moni-
tored variables that can inform oxygen therapy after
acute brain injury.
Our study has several limitations. First, the individ-
ual monitoring modalities are designed to measure
diﬀerent aspects of the oxygen cascade and cellular bio-
energetics, but each is subject to its own limitations.
Although diﬀerential spectroscopy NIRS methodolo-
gies, such as the one we used to measure haemoglobin
and [oxCCO] in this study, are subject to signiﬁcantly
more extracranial ‘contamination’ than spatially
resolved spectroscopy techniques,39 we have previously
shown that [oxCCO] is a brain-speciﬁc signal with neg-
ligible contribution from extracranial tissues.25
Furthermore, by measuring scattering and optical path-
length, we can place greater conﬁdence on the accuracy
of the measured change.40 The diﬀerential spectroscopy
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methodology that we used to measure changes in CCO
oxidation is based on the modiﬁed Beer–Lambert law
and therefore only able to quantify relative changes
in chromophore concentration from an unknown base-
line rather than measure absolute concentrations of
oxidised and reduced CCO. Nevertheless, changes in
CCO have been evaluated in animal models and
shown to be a reliable measure of intracellular energy
status.40,44,51 Microdialysate LPR is an imperfect meas-
ure of cerebral aerobic metabolism. It reﬂects the activ-
ity of cytosolic lactate dehydrogenase, which is in large
part reﬂective of intracellular NADH:NADþ ratio and
thus related to the ability of mitochondria to produce
ATP. There are therefore circumstances, including elec-
tron leak from the electron transport chain, during
which LPR can be unchanged in the face of an inability
of cells to generate energy.52 Secondly, although we
placed the microdialysis catheters in ‘at risk’ tissue in
line with consensus guidelines,27 used the same cranial
access device for pbrO2 monitoring, and applied the
NIRS optodes over the frontal region as close as pos-
sible to the insertion site of the invasive monitors, it is
likely that diﬀerent tissue volumes and regions were
interrogated by each device. Similarly, it is diﬃcult to
know exactly what region of interest is represented by
our estimate of CMRO2 which is derived from Vmca
(a relatively global measure of hemispheric CBF) and
TOI (a regional measure of tissue oxygenation).39
Finally, we investigated only 16 patients with mixed
pathology, but this is a larger patient cohort than
many investigations in this ﬁeld – for example, those
cited above – and the concept of an ischaemic pbrO2
threshold is relevant across all the pathologies included.
Spatial heterogeneity is a limiting factor in the study of
most acute brain injury types, and we have speciﬁcally
targeted analysis of the injured hemisphere using a
comprehensive array of monitoring modalities.
Overall, our ﬁndings highlight the diﬃculties in
deﬁning thresholds for hypoxia–ischaemia in the
injured brain, and the potential risks to an individual
of utilising generic targets to guide clinical manage-
ment. Diﬀusion limitation and mitochondrial dysfunc-
tion may disrupt the normal relationship between OEF,
pbrO2, and mitochondrial redox status, and this might
explain some observations of metabolic dysfunction
‘without hypoxia’ when either a diﬀusion barrier to
oxygen is present (when pbrO2 and OEF may not reﬂect
mitochondrial pO2) or much higher mitochondrial pO2
is required to maintain ATP generation. Further studies
employing multimodal monitoring, including [oxCCO],
might shed further light on the exact nature of this
metabolic derangement, and in the understanding of
oxygen diﬀusion within the microvascular and intracel-
lular environments, and oxygen utilisation. Extension
of existing computational physiological models53 may
assist in predicting oxygen diﬀusion gradients and util-
isation, exploiting measurement of TOI, pbrO2 and
CCO, and should be incorporated into future studies.
Conclusion
Standard clinical therapy following acute brain injury
fundamentally aims to avoid mitochondrial hypoxia in
order to minimise secondary tissue ischaemia and worse
clinical outcomes. pbrO2 and microdialysis-measured
LPR have been used as surrogates of mitochondrial
oxygen availability and its eﬀect on mitochondrial
redox status at the bedside, but clinical application
and interpretation of such techniques requires clearly
deﬁned thresholds for ‘ischaemia’. Our results demon-
strate an increase in oxCCO, reduction in LPR and
increase in estimated CMRO2 during and following
normobaric hyperoxia. These ﬁndings are consistent
with increased aerobic metabolism at pbrO2 levels
higher than those typically recognised as ‘ischaemic’
thresholds. Such oxygen-limited metabolism suggests
that hypoxia–ischaemia secondary to oxygen diﬀusion
limitation or mitochondrial dysfunction might be
prevalent after acute brain injury, and complicate
assessment of ischaemia using measurement of pbrO2
in isolation. Simultaneous measurement of microvascu-
lar, tissue and cellular oxygenation and metabolism has
potential to redeﬁne our understanding of ischaemia
after acute brain injury. Measurement of the oxidation
status of CCO as a bedside, continuous assessment of
mitochondrial energetics over multiple regions of inter-
est has considerable potential to guide treatment after
acute brain injury.
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